CABP Clinical Response Endpoint Gets A Boost At Ceftaroline Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel unanimously supports Forest's antibiotic for community-acquired bacterial pneumonia - as well the method of demonstrating the product's efficacy.
You may also be interested in...
Pneumonia Guidances Revisited: FDA Cmte. To Weigh Study Design Issues Again
FDA’s Anti-Infective Drugs Advisory Committee will take its third look in less than four years at standards for developing antibacterial agents to treat community-acquired bacterial pneumonia, at a meeting on Nov. 3.
Pneumonia Guidances Revisited: FDA Cmte. To Weigh Study Design Issues Again
FDA’s Anti-Infective Drugs Advisory Committee will take its third look in less than four years at standards for developing antibacterial agents to treat community-acquired bacterial pneumonia, at a meeting on Nov. 3.
Forest Must Resolve Breakpoint Issues On Road To Ceftaroline Approval
Negotiation of breakpoints appears to be the final hurdle as Forest Laboratories seeks approval for ceftaroline fosamil to treat serious skin infections and community-acquired bacterial pneumonia.